Key result
CAPD linked to higher MPO but lower NT-proBNP and troponin-I versus HD.
Why the study?
The role of plasma myeloperoxidase and its relationship with carotid intima-media thickness, troponin I, NT-proBNP, and insulin resistance in dialysis patients was unclear.
Are plasma levels of MPO, NT-proBNP, and troponin-I different between patients on CAPD compared to those on regular hemodialysis?
Observational
Are plasma levels of MPO, NT-proBNP, and troponin-I different between patients on CAPD compared to those on regular hemodialysis?
p-value: p=<0.001
CAPD is associated with higher oxidative stress markers (MPO), while HD is associated with higher cardiac biomarkers (NT-proBNP and troponin-I), possibly reflecting differences in residual renal function decline and dialysis modalities.
Dialysis modality links to distinct biomarker patterns; hypothesis-generating and should not yet alter modality selection or risk assessment.
Myeloperoxidase (MPO) is a hemoprotein that is released during inflammation and may lead to irreversible protein and lipid modification, increasing levels of oxidized low density lipoprotein, and promoting athrogenesis. Recently, it has been considered as a risk factor for cardiovascular diseases. Similarly, the measurement of carotid intima-media thickness gives an indication about the degree of atherosclerosis and prediction of clinical cardiovascular events. Elevated white blood cells counts may indicate a state of acute inflammation and follow its progression. Dialysis patients are at a high risk of developing cardiovascular disease compared with healthy subjects. The role of N-terminal pro-brain natriuretic peptide and increased cardiac troponin in identification and prognostication of cardiovascular diseases in end-stage renal disease patients has been investigated. The current study aimed to evaluate plasma MPO and its possible relationship with carotid intima-media thickness, troponin I, N-terminal pro-brain natriuretic peptide (NT-proBNP), and insulin resistance as measured by homeostatic model assessment (HOMA index) in a cohort of Saudi patients who are undergoing hemodialysis (HD) vs. continuous ambulatory peritoneal dialysis for end-stage renal disease. Plasma MPO was significantly higher in patients on continuous ambulatory peritoneal dialysis (CAPD) than in those on HD and in normal subjects (P<0.001). Conversely, NT-proBNP plasma levels were significantly higher in patients on HD (both predialysis and postdialysis) than in those on CAPD (P<0.01) and than normal subjects. Similarly, plasma troponin-I levels were significantly higher in patients on HD compared with those of CAPD and than normal subjects (P<0.001). Plasma troponin-I and NT-proBNP levels were positively correlated in the 3 groups namely those on CAPD, Pre-HD, and post-HD (r: 0.464 and P=0.047; r: 0.330 and P=0.013; and r: 0.452 and P=0.024), respectively. There was no correlation between the MPO level and carotid intima-media thickness (P>0.05). However, plasma MPO level correlated positively with the white blood cell count in patients on CAPD and in those on HD (P<0.05). Our findings suggest an increased oxidative stress in CAPD patients compared with HD patients, while the reported difference in plasma NT-proBNP and troponin-I may be related to the rapid decline of residual renal function in HD and type of membrane used in the HD dialysis procedure itself.
No takes yet. Share an insight, caveat, or question.
Al-Hweish et al. (2010) conducted an observational in End-stage renal disease. Continuous ambulatory peritoneal dialysis (CAPD) vs. Hemodialysis (HD) and normal subjects was evaluated on Plasma MPO, NT-proBNP, and troponin-I levels (p=<0.001). Continuous ambulatory peritoneal dialysis was associated with significantly higher plasma MPO levels compared to hemodialysis (P<0.001), whereas hemodialysis patients had higher NT-proBNP and troponin-I.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: